Skip to main content

Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer

  • Chapter

Part of the Series in Biomedical Engineering book series (BIOMENG)

Abstract

Irreversible electroporation (IRE) is a new non-thermal ablation modality that uses short pulses of DC electric current to create irreversible pores in the cell membrane thus causing cell death. This method has been shown by Rubinsky et al. to have significant advantages in ablating prostatic tissue, such as rapid lesion creation, rapid lesion resolution, sparing of structures such as vessels, nerves and urethra, and uniform destruction throughout the IRE lesion (1). The underlying principles are well covered in other chapters in this book. This discussion will deal with the first human applications of IRE and whether its theoretical promises of improved clinical outcomes, have been delivered. For a number of reasons, including the ability to carry out extensive post operative biopsies to confirm the adequate ablation of cancer, the first human experience was carried out in the prostate.

Keywords

  • Prostate Cancer
  • Radical Prostatectomy
  • Localize Prostate Cancer
  • Neurovascular Bundle
  • Watchful Waiting

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-642-05420-4_10
  • Chapter length: 13 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-3-642-05420-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   199.99
Price excludes VAT (USA)
Hardcover Book
USD   219.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rubinsky, B., Onik, G., Mikus, P.: Irreversible electroporation: a new ablation modality–clinical implications. Technol. Cancer Res. Treat. 6(1), 37–48 (2007)

    Google Scholar 

  2. Onik, G., Narayan, P., Vaughan, D., et al.: Focal nerve sparing cryoablation for the treatment of primary prostate cancer: A new approach to preserving potency. Urology 60(1), 109–114 (2002)

    CrossRef  Google Scholar 

  3. Onik, G., Vaughan, D., Lotenfoe, R., Dineen, M., Brady, J.: Male lumpectomy: focal therapy for prostate cancer using cryoablation. Urology 70(suppl. 6), 16–21 (2007)

    CrossRef  Google Scholar 

  4. Bahn, D.K., Silverman, P., Lee, F., Badalament, R., Bahn, E.D., Rewcastle, J.C.: Focal prostate cryoablation: initial results show cancer control and potency preservation. J. Endourol. 20(9), 688–692 (2006)

    CrossRef  Google Scholar 

  5. Lambert, E.H., Bolte, K., Masson, P., Katz, A.E.: Focal cryosurgery: encouraging health outcomes for uni-focal prostate cancer. Urology 69(6), 1117–1120 (2007)

    CrossRef  Google Scholar 

  6. Bahn, D.K., Lee, F., Bandalament, R., et al.: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(suppl. 1, 2), 3–11 (2002)

    CrossRef  Google Scholar 

  7. Bostwick, D.G., Waters, D.J., Farley, E.R., Meiers, I., Rukstalis, D., Cavanaugh, W.A., Ragde, H., Dineen, M.K., Bahn, D., Scionti, S., Babian, R., Ellis, D.S., Rewcastle, J.C., Burke, H.B., Andriole, G.L., Onik, G., Barqawi, A.E., Maksem, J., Barzell, W.E.: Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida (February 24, 2006); Urology 70(suppl. 6), 42–44 (December 2007)

    Google Scholar 

  8. Santiago, R.J., Wu, L., Harris, E., Fox, K., Schultz, D., Glick, J., Solin, L.J.: Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 233–240 (2004)

    CrossRef  Google Scholar 

  9. Messing, E.M., Thompson, I.: Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol. Clin. North Am. 30(4), 687–702 (2003)

    CrossRef  Google Scholar 

  10. Djvan, B., Susani, M., Bursa, B., et al.: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Techniques in Urology 5(3), 139–142 (1999)

    Google Scholar 

  11. Villars, A., McNeal, J.E., Freiha, F.S., et al.: Multiple cancers in the prostate. Morphological features of clinically recognized vs. incidental tumors. Urology 60(2A), 19–25 (2002)

    CrossRef  Google Scholar 

  12. Noguchi, M., Stamey, T.A., McNeal, J.E., et al.: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary tumors. J. Uril. 170(2pt), 459–463 (2003)

    CrossRef  Google Scholar 

  13. Rukstalis, D.B., Goldknopf, J.L., Crowley, E.M., et al.: Prostate cryoablation: A scientific rationale for future modifications. Urology 60(2A), 19–25 (2002)

    CrossRef  Google Scholar 

  14. Crawford, E.D., Wilson, S.S., Torkko, K.C., et al.: Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int. 96(7), 999–1004 (2005)

    CrossRef  Google Scholar 

  15. Gary Onik, M.D., Winston Barzell, M.D.: Transperineal 3D Mapping Biopsy of the Prostate: An Essential Tool in Selecting Patients for Focal Prostate Cancer Therapy. Urologic Oncology: Seminars and Original Investigations (in Press)

    Google Scholar 

  16. Barzell, W.E., Melamed, M.R.: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology 70(suppl. 6), 27–35 (2007)

    CrossRef  Google Scholar 

  17. Health Care Financing Administration. Medicare Coverage Policy: Decisions. Bagley GP. Cryosurgery ablation of the prostate (#CAG-00031), http://www.hcfa.gov/coverage/8b3-f1.htm (accessed November 7, 2001)

  18. Donnelly, B.J., Saliken, J.C., Brasher, P., et al.: Randomized controlled trial comparing external beam radiation and cryoablation in localized prostate cancer. In: Proceedings of the American Urological Association of 2007 (2007), Abstract #1141

    Google Scholar 

  19. Eggener, S.E., Scardino, P.T., Carroll, P.R., Zelefsky, M.J., Sartor, O., Hricak, H., Wheeler, T.M., Fine, S.W., Trachtenberg, J., Rubin, M.A., Ohori, M., Kuroiwa, K., Rossignol, M., Abenhaim, L.: International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J. Urol. 178(6), 2260–2267 (2007) (Epub October 15, 2007)

    CrossRef  Google Scholar 

  20. Ahmed, H.U., Pendse, D., Illing, R., Allen, C., van der Meulen, J.H., Emberton, M.: Will focal therapy become a standard of care for men with localized prostate cancer? Nat. Clin. Pract. Oncol. 4(11), 632–642 (2007)

    CrossRef  Google Scholar 

  21. Mouraviev, V., Mayes, J.M., Sun, L., Madden, J.F., Moul, J.W., Polascik, T.J.: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110(4), 906–910 (2007)

    CrossRef  Google Scholar 

  22. Neumann, E., Schaefer-Ridder, M., Wang, Y., Hofschneider, P.H., et al.: Gene transfer into mouse lyoma cells by electroporation in high electric fields. J. EMBO 1, 841–845 (1982)

    Google Scholar 

  23. Mir, L.M., Belehradek, M., Domenge, C., Luboniski, B., Orlowski, S., Belehradek, J., Schwaab, B., Luboniski, B., Paoletti, C.: Electrochemotherapy, a novel antitumor treatment: first clinical trial. C. R. Acad. Sci. Ser. III 313, 613–618 (1991)

    Google Scholar 

  24. Davalos, R.V., Mir, L.M., Rubinsky, B.: Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering 33(2), 223–231 (2005)

    CrossRef  Google Scholar 

  25. Onik, G., Mikus, P., Rubinsky, B.: Irreversible electroporation: implications for prostate ablation. Technol. Cancer Res. Treat. 6(4), 295–300 (2007)

    Google Scholar 

  26. Miller, L., Leor, J., Rubinsky, B.: Cancer cells ablation with irreversible electroporation. Technology in Cancer Research and Treatment 4(6), 1–6 (2005)

    Google Scholar 

  27. Ellis, D., Jones, J., Pisters, L., et al.: Subtotal/Partial gland prostate cryoablation: Results of 341 patients from multiple centers tracked with the cold registry. Presented AUA 2008, Orlando FL (2008), Abstract Number:08-AB-95484-AUA

    Google Scholar 

  28. Lavee, J., Onik, G., Mikus, P., Rubinsky, B.: A novel non-thermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surg. Forum 10(2), E162–E167 (2007)

    CrossRef  Google Scholar 

  29. Donnelly, B.J., Salikan, J.C., Ernst, D.S., et al.: Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 60(4), 645 (2002)

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Onik, G., Rubinsky, B. (2010). Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer. In: Rubinsky, B. (eds) Irreversible Electroporation. Series in Biomedical Engineering. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05420-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05420-4_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05419-8

  • Online ISBN: 978-3-642-05420-4

  • eBook Packages: EngineeringEngineering (R0)